Summary by Moomoo AI
Pfizer Inc., the pharmaceutical giant, filed a Registration Statement on Form S-8 with the U.S. Securities and Exchange Commission (SEC) on February 23, 2024. This filing is in connection with the company's 2019 Stock Plan following the completion of its acquisition of Seagen Inc. on December 14, 2023. The registration statement pertains to the offering and sale of an additional 67,734,387 shares of Pfizer's common stock. These shares were added to the share reserves under the 2019 Stock Plan as a result of the acquisition. The documents required for the registration statement will be delivered to the participants of the plan and are available upon request. Pfizer's recent Annual Report and other relevant documents have been incorporated by reference into this registration statement, which will be updated with any subsequent filings with the SEC.